immunocore-logo-2018
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
October 18, 2021 07:30 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
immunocore-logo-2018
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
September 22, 2021 18:00 ET | Immunocore Holdings Limited
Press Release Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine Tebentafusp demonstrated prolonged overall...
immunocore-logo-2018
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
September 20, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated...
immunocore-logo-2018
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
September 13, 2021 16:30 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
September 10, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 September 2021) Immunocore Holdings plc...
immunocore-logo-2018
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
September 08, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...
immunocore-logo-2018
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
August 24, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp...
immunocore-logo-2018
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) submission for tebentafusp in metastatic uveal melanoma...
immunocore-logo-2018
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:05 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
May 27, 2021 16:30 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...